IL126152A0 - Recombinant adenoviral vectors for human tumor gene therapy - Google Patents

Recombinant adenoviral vectors for human tumor gene therapy

Info

Publication number
IL126152A0
IL126152A0 IL12615297A IL12615297A IL126152A0 IL 126152 A0 IL126152 A0 IL 126152A0 IL 12615297 A IL12615297 A IL 12615297A IL 12615297 A IL12615297 A IL 12615297A IL 126152 A0 IL126152 A0 IL 126152A0
Authority
IL
Israel
Prior art keywords
gene therapy
human tumor
adenoviral vectors
recombinant adenoviral
tumor gene
Prior art date
Application number
IL12615297A
Other languages
English (en)
Original Assignee
Rhone Poulenc Rorer Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Rhone Poulenc Rorer Sa filed Critical Rhone Poulenc Rorer Sa
Publication of IL126152A0 publication Critical patent/IL126152A0/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/10—Cells modified by introduction of foreign genetic material
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2799/00—Uses of viruses
    • C12N2799/02—Uses of viruses as vector
    • C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
    • C12N2799/022—Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from an adenovirus

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Wood Science & Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Immunology (AREA)
  • General Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Plant Pathology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Virology (AREA)
  • Physics & Mathematics (AREA)
  • Epidemiology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
IL12615297A 1996-03-14 1997-03-12 Recombinant adenoviral vectors for human tumor gene therapy IL126152A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR9603207A FR2746110B1 (fr) 1996-03-14 1996-03-14 Methode de traitement par therapie genique des tumeurs humaines et virus recombinants correspondants
PCT/FR1997/000435 WO1997034009A1 (fr) 1996-03-14 1997-03-12 Vecteurs adenoviraux recombinants pour la therapie genique des tumeurs humaines

Publications (1)

Publication Number Publication Date
IL126152A0 true IL126152A0 (en) 1999-05-09

Family

ID=9490181

Family Applications (1)

Application Number Title Priority Date Filing Date
IL12615297A IL126152A0 (en) 1996-03-14 1997-03-12 Recombinant adenoviral vectors for human tumor gene therapy

Country Status (19)

Country Link
US (1) US20030082150A1 (de)
EP (1) EP0889969B1 (de)
JP (1) JP2000507229A (de)
KR (1) KR19990087718A (de)
CN (1) CN1218512A (de)
AT (1) ATE309382T1 (de)
AU (1) AU732288B2 (de)
BR (1) BR9707994A (de)
CA (1) CA2248612A1 (de)
CZ (1) CZ295967B6 (de)
DE (1) DE69734574T2 (de)
DK (1) DK0889969T3 (de)
ES (1) ES2252779T3 (de)
FR (1) FR2746110B1 (de)
HU (1) HUP9902150A3 (de)
IL (1) IL126152A0 (de)
NO (1) NO984052L (de)
SK (1) SK124698A3 (de)
WO (1) WO1997034009A1 (de)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU4668797A (en) * 1996-10-07 1998-05-05 Ludwig Institute For Cancer Research Replication-defective adenoviruses for cancer immunotherapy
CA2388337C (en) 1999-10-22 2013-01-08 Aventis Pasteur Limited Method of inducing and/or enhancing an immune response to tumor antigens
DK1282702T3 (da) * 2000-05-10 2007-04-02 Sanofi Pasteur Ltd Immunogene polypeptider, som er kodet af KAGE-minigener, og anvendelser deraf
US7306792B2 (en) * 2001-03-27 2007-12-11 New York University Tumor therapy with alphavirus-based and high affinity laminin receptor-targeted vectors
ES2290449T3 (es) 2002-04-09 2008-02-16 Sanofi Pasteur Limited Acido nucleico de cea modificado y vectores de expresion.
JP2005523942A (ja) * 2002-04-30 2005-08-11 アヴィオル セラピューティクス インコーポレイテッド 免疫療法のためのアデノウイルスベクター
CN1327000C (zh) * 2002-09-06 2007-07-18 中国人民解放军军事医学科学院基础医学研究所 靶向黑色素瘤的可复制性腺病毒穿梭载体及腺病毒
EP1556082A1 (de) * 2002-10-22 2005-07-27 Aventis Pasteur Limited Impfstoffe gegen krebs mit hochdosierten zytokinen als adjuvans
CA2550583C (en) * 2003-10-08 2013-01-15 Sanofi Pasteur, Inc. Modified cea /b7 vector
SG11201507393TA (en) 2013-03-14 2015-10-29 Salk Inst For Biological Studi Oncolytic adenovirus compositions
KR102608590B1 (ko) 2014-09-24 2023-12-01 솔크 인스티튜트 포 바이올로지칼 스터디즈 종양 살상 바이러스 및 이의 사용방법
WO2017147265A1 (en) 2016-02-23 2017-08-31 Salk Institute For Biological Studies High throughput assay for measuring adenovirus replication kinetics
WO2017147269A1 (en) 2016-02-23 2017-08-31 Salk Institute For Biological Studies Exogenous gene expression in therapeutic adenovirus for minimal impact on viral kinetics
EP3532082A4 (de) 2016-12-12 2020-08-26 Salk Institute for Biological Studies Auf tumoren gerichtete synthetische adenoviren und verwendungen davon
CN112292449A (zh) 2018-04-09 2021-01-29 萨克生物研究学院 具有增强的复制特性的溶瘤腺病毒组合物

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5342774A (en) * 1991-05-23 1994-08-30 Ludwig Institute For Cancer Research Nucleotide sequence encoding the tumor rejection antigen precursor, MAGE-1
US6235525B1 (en) * 1991-05-23 2001-05-22 Ludwig Institute For Cancer Research Isolated nucleic acid molecules coding for tumor rejection antigen precursor MAGE-3 and uses thereof
US5620886A (en) * 1993-03-18 1997-04-15 Ludwig Institute For Cancer Research Isolated nucleic acid sequence coding for a tumor rejection antigen precursor processed to at least one tumor rejection antigen presented by HLA-A2
SK282843B6 (sk) * 1993-07-13 2002-12-03 Rhone-Poulenc Rorer S. A. Defektný rekombinantný adenovírus a farmaceutický prostriedok s jeho obsahom

Also Published As

Publication number Publication date
DK0889969T3 (da) 2006-03-27
KR19990087718A (ko) 1999-12-27
DE69734574T2 (de) 2006-07-13
US20030082150A1 (en) 2003-05-01
SK124698A3 (en) 1999-05-07
ATE309382T1 (de) 2005-11-15
CN1218512A (zh) 1999-06-02
AU2164197A (en) 1997-10-01
EP0889969B1 (de) 2005-11-09
FR2746110A1 (fr) 1997-09-19
NO984052D0 (no) 1998-09-03
DE69734574D1 (de) 2005-12-15
HUP9902150A2 (hu) 1999-11-29
WO1997034009A1 (fr) 1997-09-18
CA2248612A1 (fr) 1997-09-18
ES2252779T3 (es) 2006-05-16
BR9707994A (pt) 1999-07-27
CZ291598A3 (cs) 1998-12-16
JP2000507229A (ja) 2000-06-13
NO984052L (no) 1998-09-03
EP0889969A1 (de) 1999-01-13
AU732288B2 (en) 2001-04-12
CZ295967B6 (cs) 2005-12-14
FR2746110B1 (fr) 1998-04-17
HUP9902150A3 (en) 2000-12-28

Similar Documents

Publication Publication Date Title
IL126152A0 (en) Recombinant adenoviral vectors for human tumor gene therapy
TW581808B (en) Compounds for immunotherapy of prostate cancer and methods for their use
MY119276A (en) Pharmaceutical composition for immunomodulation based on peptides and adjuvants
WO1999033869A3 (en) Compounds for immunotherapy and diagnosis of breast cancer and methods for their use
NZ516381A (en) Lung tumor proteins in the therapy and diagnosis of lung cancer
WO1998037093A3 (en) Compounds for immunotherapy of prostate cancer and methods for their use
HUT72558A (en) Defective adenovirus vectors and use thereof in gene therapy
PL354348A1 (en) Compounds and methods for therapy and diagnosis of lung cancer
EP1090924B8 (de) Von cyclophilin b abstammende tumorantigen-peptide
UA66417C2 (en) Recombinant adenovirus affecting canines, pharmaceutical composition
NZ281409A (en) Medicaments for cancer treatment using peptides based on a 9 AA epitiope derived from mage -3 that induces ctls
PL314239A1 (en) Recombinated adenovirus vector and method of using it
AU2001287639A1 (en) Trp8, trp9 and trp10, markers for cancer
AUPN568095A0 (en) Anti-Galalpha(1,3)Gal antibody binding peptides
AU2003242305A1 (en) Hla-a24-restricted cancer antigen peptide
BR9908823A (pt) Compostos e processos para terapia e diagnóstico de câncer de pulmão
CA2234263A1 (fr) Composition pharmaceutique contre les tumeurs et infections a papillomavirus
NO953684L (no) Fremgangsmåte for fremstilling av kreftvaksiner
WO1999032516A3 (en) Pharmaceutical compositions containing the long pentraxin ptx3
IL146125A0 (en) Novel quinones as disease therapies
EP1455840A4 (de) Behandlung von krebs bei menschen mit adenovirus-vektor tnf-alpha
GR3024379T3 (en) Peptides with organo-protective activity, the process for preparing them and their use in therapy
WO2000061756A3 (en) Compounds for immunotherapy and diagnosis of breast cancer and methods for their use
IL114382A (en) Lymphotoxin for use as a medicament for cancer therapy and use thereof in the manufacture of such medicament
NZ510154A (en) A tumour antigen protein and gene therefor, tumour antigen peptides and derivatives thereof in medicaments and prophylactics